STOCKHOLM, SE / ACCESS Newswire / December 5, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Oppenheimer Movers in Rare Disease Summit:
Location: New York, USA
Format: Fireside Chat and 1×1 meetings
Presentation Date and Time: Thursday, December 11 at 9:00 AM ET
Participant: Megan Richards, VP of IR, Communications, and Portfolio Strategy
The company's management team will also be available for meetings at the conference.
For more information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [email protected]
Hans Jeppsson, CFO, tel: +46 70 553 14 65, [email protected]
About Vicore Pharma
Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com
Attachments
Vicore to present at the Oppenheimer Movers in Rare Disease Summit
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire